19 June 2018 - New indication supports Amgen's commitment to reduce the risk of recurrent cardiovascular events faced by heart attack and stroke survivors.

Today Amgen Canada announced that Health Canada has now indicated Repatha as an adjunct to diet and standard of care therapy (including moderate to high-intensity statin therapy alone or in combination with other lipid-lowering therapy), to reduce the risk of myocardial infarction, stroke, and coronary revascularisation in adult patients with atherosclerotic cardiovascular disease.

In the Repatha cardiovascular outcomes study (FOURIER), Repatha reduced the risk of heart attack by 27%, the risk of stroke by 21%, and the risk of coronary revascularisation by 22%.

Read Amgen press release